You are here

Amgen

[forum discussion]New neuro sales force for Amgen migraine drug erenumab

[forum discussion]New neuro sales force for Amgen migraine drug erenumab

Cafepharma Message Boards

Flag link:

Regeneron-Sanofi food allergy drug succeeds mid-stage study

Regeneron-Sanofi food allergy drug succeeds mid-stage study

Yahoo/Reuters

eosinophilic esophagitis

Flag link:

Mylan and Biocon biosimilar of Amgen’s Neulasta hit with manufacturing-related CRL

Mylan and Biocon biosimilar of Amgen’s Neulasta hit with manufacturing-related CRL

Fierce Pharma

Flag link:

PCSK9 court saga drags on for Sanofi, Regeneron and Amgen

PCSK9 court saga drags on for Sanofi, Regeneron and Amgen

Biopharma Dive

PCSK9 inhibitors

Flag link:

Sanofi and Regeneron, seeking to shield Dupixent, lose first IPR try against Amgen

Sanofi and Regeneron, seeking to shield Dupixent, lose first IPR try against Amgen

Fierce Pharma

Flag link:

Amgen-partnered Immatics bags a $58M round to fund its first clinical steps on new T-cell tech for cancer

Amgen-partnered Immatics bags a $58M round to fund its first clinical steps on new T-cell tech for cancer

Endpoints

Flag link:

Abbvie, Amgen Deal on Humira Biosimilars Likely to Cost CMS More Than $1B

Abbvie, Amgen Deal on Humira Biosimilars Likely to Cost CMS More Than $1B

RAPS.org

Flag link:

How Good Is AbbVie's Humira Deal With Amgen?

How Good Is AbbVie's Humira Deal With Amgen?

Motley Fool

Flag link:

Under Amgen and AbbVie agreement, rival drug to AbbVie's Humira expected to launch in 2023

Under Amgen and AbbVie agreement, rival drug to AbbVie's Humira expected to launch in 2023

Marketwatch

Flag link:

Amgen targets China in cancer biosimilar development deal with Simcere

Amgen targets China in cancer biosimilar development deal with Simcere

Fierce Pharma

drug development

Flag link:

Amgen reaffirms 2017 guidance in wake of Hurricane Maria

Amgen reaffirms 2017 guidance in wake of Hurricane Maria

Marketwatch

drug manufacturing

Flag link:

Pharma executives wary of value-based deals, but see the potential benefits: PwC

Pharma executives wary of value-based deals, but see the potential benefits: PwC

Fierce Pharma

value-based contracts

Flag link:

Sanofi and Amgen, eyeing boost for PCSK9 use, tout benefits for diabetes patients

Sanofi and Amgen, eyeing boost for PCSK9 use, tout benefits for diabetes patients

Fierce Pharma

PCSK9 inhibitors

Flag link:

Why Amgen, Lilly, J&J Are Interested In These Small Biotechs

Why Amgen, Lilly, J&J Are Interested In These Small Biotechs

Investors Business Daily

Bavarian Nordic

Biohaven Pharmaceuticals

Flag link:

FDA commish cheers on biosimilars as Amgen, Allergan score OK for knockoff of Roche’s Avastin

FDA commish cheers on biosimilars as Amgen, Allergan score OK for knockoff of Roche’s Avastin

Endpoints

Flag link:

Insurers, doctors battle over new heart disease drugs

Insurers, doctors battle over new heart disease drugs

CNBC

cardiovascular disease

PCSK9 inhibitors

Flag link:

AstraZeneca, Amgen whip up some blockbuster excitement with a possible game-changing asthma drug

AstraZeneca, Amgen whip up some blockbuster excitement with a possible game-changing asthma drug

Endpoints

Flag link:

The Only 2 Biotech Stocks With a Higher Dividend Yield Than the S&P 500

The Only 2 Biotech Stocks With a Higher Dividend Yield Than the S&P 500

Motley Fool

Gilead Sciences

Flag link:

Key FDA Regulatory Events to Watch Out for in Sep 2017

Key FDA Regulatory Events to Watch Out for in Sep 2017

Yahoo/Zacks.com

PTC Therapeutics

Flag link:

Is the System Rigged Against Biosimilars?

Is the System Rigged Against Biosimilars?

Motley Fool

Flag link: